AI industry giants, including the CEOs of OpenAI, Anthropic, and Microsoft AI, have set aside their competitive differences to jointly urge Congress to implement stronger safeguards against AI-enabled bioweapons. They co-signed an open letter, along with 85 other experts in tech, biology, and national security, emphasizing the growing risk of AI lowering the barriers for malicious actors to develop biological weapons.
The letter specifically calls for mandatory screening of all orders for synthetic DNA and RNA, which are the fundamental building blocks for viruses and other pathogens. While some manufacturers currently perform voluntary screenings, the letter seeks to make this a legal requirement across the entire industry. It also proposes that companies selling these materials maintain detailed records of orders and specifications to assist in future biosecurity investigations.
The urgency for such regulations stems from the rapid advancements and widespread availability of AI models. Studies have shown that generative AI tools have reached 53% of the global population in just three years, outpacing the adoption rates of personal computers and the internet. Furthermore, publicly available AI models have demonstrated the capacity to provide information on how to create and disseminate biological weapons.
OpenAI is actively funding research to mitigate these risks, allocating $1 million to various organizations, including the Nuclear Threat Initiative (NTI). NTI's project aims to improve international information sharing on potential AI biothreats and monitor for the misuse of AI in developing new biological weapons. This proactive approach by tech companies, coupled with the bipartisan support for legislation like the Biosecurity Modernization and Innovation Act of 2026, highlights a unified effort to address this emerging threat.
The initiative is supported by organizations like the conservative-leaning Foundation for American Innovation and the nonpartisan Institute for Progress. Even some synthetic material manufacturers, such as Twist Bioscience and Ansa Biotechnologies, have signed the letter, indicating industry acceptance of the proposed regulations. This broad consensus underscores the perceived gravity of the threat and the need for immediate, concerted action.
